[CRL] Charles River Laboratories International, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Commercial Physical & Biological Resarch

Market Capitalization:

Exchange: NYSE

The data is delayed by 15 minutes.

 

Price: 75.72 Change: 1.37 (1.84%)
Ext. hours: Change: 0 (0%)

chart CRL

Refresh chart

Strongest Trends Summary For CRL

CRL is in the medium-term up 8% in 6 months. In the long-term up 99% above S&P in 12 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Charles River Laboratories International, Inc., together with its subsidiaries, provides research models and associated services, and outsourced preclinical services to accelerate the drug discovery and development process. It operates through two segments, Research Models and Services (RMS), and Preclinical Services (PCS). The RMS segment produces and sells research model strains, principally genetically and microbiologically defined purpose-bred rats and mice for use by researchers. This segment also offers a range of services to assist customers in the drug discovery and development process, which include genetically engineered models and services, insourcing solutions, discovery research services, and research animal diagnostic services; endotoxin and microbial detection products and services; and avian vaccine products and services. The PCS segment provides preclinical services, including in vivo and in vitro studies, supporting laboratory services, and strategic preclinical consulting and program manage

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -6.09% Sales Growth - Q/Q-2.77% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA6.9% ROE18.39% ROI8.26%
Current Ratio2.27 Quick Ratio1.95 Long Term Debt/Equity2.2 Debt Ratio0.39
Gross Margin36.67% Operating Margin13.72% Net Profit Margin9.67% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-63.73 M Cash From Investing Activities-36.49 M Cash From Operating Activities96.68 M Gross Profit132.78 M
Net Profit48.51 M Operating Profit55.73 M Total Assets1.89 B Total Current Assets629.65 M
Total Current Liabilities276.53 M Total Debt772.77 M Total Liabilities1.18 B Total Revenue339.57 M
Technical Data
High 52 week148.55 Low 52 week104.82 Last close139.53 Last change0.92%
RSI69.48 Average true range3.4 Beta0.74 Volume208.32 K
Simple moving average 20 days4.9% Simple moving average 50 days5.02% Simple moving average 200 days3.11%
Performance Data
Performance Week1.76% Performance Month10.41% Performance Quart8.16% Performance Half8.63%
Performance Year11.62% Performance Year-to-date23.28% Volatility daily1.29% Volatility weekly2.87%
Volatility monthly5.89% Volatility yearly20.41% Relative Volume241.93% Average Volume341.34 K
New High New Low

News

2020-05-21 07:13:01 | A Rising Share Price Has Us Looking Closely At Charles River Laboratories International, Inc.'s NYSE:CRL P/E Ratio

2020-05-09 09:12:07 | At US$160, Is It Time To Put Charles River Laboratories International, Inc. NYSE:CRL On Your Watch List?

2020-05-08 00:31:10 | Charles River Laboratories International Inc CRL Q1 2020 Earnings Call Transcript

2020-05-07 18:52:20 | Edited Transcript of CRL earnings conference call or presentation 7-May-20 1:30pm GMT

2020-05-07 08:25:12 | Charles River Laboratories CRL Q1 Earnings and Revenues Surpass Estimates

2020-05-07 07:00:00 | Charles River Laboratories Announces First-Quarter 2020 Results

2020-04-30 12:34:04 | Charles River Laboratories CRL Reports Next Week: Wall Street Expects Earnings Growth

2020-04-29 12:08:09 | Why Horizon Kinetics is Bullish on Charles River Laboratories CRL Stock?

2020-04-20 15:24:00 | Earnings Season Preview: Medpace Near Buy Zone With Quarterly Report Due

2020-04-19 15:54:42 | Covid-19 Shines Spotlight on Clarivate

2020-04-16 08:40:30 | How Does Charles River Laboratories International's NYSE:CRL P/E Compare To Its Industry, After Its Big Share Price Gain?

2020-04-16 08:30:00 | Charles River Laboratories Schedules First-Quarter 2020 Earnings Release and Conference Call

2020-03-30 08:30:00 | Charles River Laboratories and Deciphex Form a Partnership to Enhance Drug Discovery & Development With Digital Pathology

2020-03-25 06:26:29 | How Does Charles River Laboratories International's NYSE:CRL P/E Compare To Its Industry, After The Share Price Drop?

2020-03-22 22:56:25 | Is Charles River Laboratories International Inc. CRL Relatively A Good Stock To Buy?

2020-03-10 08:30:00 | Charles River Laboratories To Participate In Barclays Global Healthcare Conference

2020-03-04 08:00:00 | Charles River Laboratories Adds Nancy C. Andrews, M.D., Ph.D., to Board of Directors

2020-02-13 07:11:46 | What Did Charles River Laboratories International, Inc.'s NYSE:CRL CEO Take Home Last Year?

2020-02-13 06:37:21 | Charles River Laboratories International, Inc. Analysts Are Pretty Bullish On The Stock After Recent Results

2020-02-12 12:00:05 | Here's Why Momentum Investors Will Love Charles River Laboratories CRL

2020-02-12 10:30:00 | Charles River Labs Soars to a New High and More Strength Is Coming

2020-02-12 09:15:02 | Charles River CRL Hits Fresh High: Is There Still Room to Run?

2020-02-11 17:25:25 | Edited Transcript of CRL earnings conference call or presentation 11-Feb-20 1:30pm GMT

2020-02-11 09:19:00 | Charles River Laboratories Reports Q4 Above Our Expectations; Raising FVE on Solid 2020 Guidance

2020-02-11 08:25:01 | Charles River Laboratories CRL Q4 Earnings and Revenues Beat Estimates

2020-02-11 07:00:00 | Charles River Laboratories Announces Fourth-Quarter and Full-Year 2019 Results and Provides 2020 Guidance

2020-02-06 09:18:02 | Zacks.com featured highlights include: MSFT, RUTH, RMD, CDNS, CRL and MXIM

2020-02-05 08:44:59 | 6 GARP Stocks to Scoop Up for Maximum Returns

2020-02-04 12:30:05 | Charles River Laboratories CRL Earnings Expected to Grow: Should You Buy?

2020-01-22 07:46:12 | Zacks.com featured highlights include: Design System, The Toro Company, Charles River Laboratories International and ICON

2020-01-21 16:30:00 | Charles River Laboratories Schedules Fourth-Quarter 2019 Earnings and 2020 Guidance Release and Conference Call

2020-01-21 09:11:02 | 4 GARP Stocks for a Winning Portfolio

2020-01-19 08:16:21 | Here's Why We Think Charles River Laboratories International NYSE:CRL Is Well Worth Watching

2020-01-17 15:34:17 | Still Time to Ride the Wave With Charles River

2020-01-17 09:15:02 | Icon PLC ICLR Hits Fresh High: Is There Still Room to Run?

2020-01-16 08:00:00 | Charles River Laboratories and Fios Genomics Form a Strategic Alliance to Provide Bioinformatics-driven Drug Discovery and Safety Assessment

2020-01-15 12:10:05 | Will Charles River CRL Beat Estimates Again in Its Next Earnings Report?

2020-01-13 08:30:00 | Charles River and Takeda Announce Scientific Collaboration to Identify and Develop Preclinical Candidates

2020-01-13 08:00:00 | Charles River Laboratories to Present at J.P. Morgan Healthcare Conference

2020-01-08 09:15:02 | Charles River CRL Soars to 52-Week High, Time to Cash Out?

2020-01-07 11:50:00 | Top-Rated Stocks: Charles River Labs International Sees Composite Rating Climb To 96

2020-01-03 08:30:00 | Charles River Laboratories Completes the Acquisition of HemaCare Corporation

2019-12-26 10:56:52 | How Did Charles River Laboratories International Inc. CRL Compare Against Top Hedge Fund Stocks in 2019?

2019-12-24 06:44:28 | Is Charles River Laboratories International, Inc.'s NYSE:CRL P/E Ratio Really That Good?

2019-12-18 19:35:00 | SHAREHOLDER ALERT: WeissLaw LLP Investigates HemaCare Corporation

2019-12-16 14:33:00 | ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of HemaCare Corporation

2019-12-16 07:00:00 | Charles River Laboratories to Acquire HemaCare Corporation

2019-12-10 08:00:00 | Charles River Announces Strategic Partnership with Bit Bio, Increasing Portfolio of Translational Drug Discovery Technologies

2019-12-10 07:51:57 | Devon Park Drive building hits the market, could sell for a big premium

2019-12-09 16:30:00 | Distributed Bio Launches Cosmic Antibody Library, Provides Charles River Clients Exclusive Access